Details

Autor(en) / Beteiligte

• Kelleher, Nicholas
• Gallardo, David
• González-Campos, José
• Hernández-Rivas, Jesús M
• Montesinos, Pau
• Sarrá, Josep
• Gil, Cristina
• Barba, Pere
• Guàrdia, Ramon
• Brunet, Salut
• Bernal, Teresa
• Martínez, Maria-Pilar
• Abella, Eugènia
• Bermúdez, Arantxa
• Sánchez-Delgado, Magdalena
• Antònia, Cladera
• Gayoso, Jorge
• Calbacho, María
• Ribera, Josep-Maria

Titel

Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

Ist Teil von

• Leukemia & lymphoma, 2016-01, Vol.57 (1), p.86-91

Ort / Verlag

United States

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Acute lymphoblastic leukemia (ALL) following solid organ or hematologic malignancy (secondary ALL, s-ALL) is not well characterized. We analyzed the characteristics and outcome of patients with s-ALL and compared them with those of patients with de novo- ALL. Of 448 patients, 24 (5%) had previous neoplasia. Sixteen patients had received previous cytotoxic therapy (therapy-associated ALL, t-ALL), and eight had not (antecedent-malignancy ALL, am-ALL). Except for more advanced age in patients with s-ALL, no statistically significant differences were observed in WBC count, CNS involvement, immunophenotype or cytogenetics between the groups, nor in complete remission (t-ALL: 94%; am-ALL: 75%; de novo-ALL: 85%), 3-year remission duration (58%; 50%; 72%), overall survival (71%; 38%; 60%) or event-free survival (53%, 38%; 53%). Our study did not show poor clinical or cytogenetic features or inferior outcome in ALL patients with antecedent neoplastic disease, irrespective of the type of treatment received for the neoplasia.